Lawley Pharmaceuticals

Lawley Pharmaceuticals is an Australian-based pharmaceutical company that specializes in the development, manufacturing, and distribution of hormone replacement therapies. The company is known for its focus on transdermal delivery systems, which provide an alternative to oral and injectable hormone therapies.

History

Lawley Pharmaceuticals was founded in 1995 by Michael Buckley. The company initially focused on the development of testosterone replacement therapies for men with hypogonadism. Over the years, Lawley Pharmaceuticals expanded its product line to include treatments for menopause and other hormone-related conditions.

Products

Lawley Pharmaceuticals offers a range of hormone replacement therapies, primarily in the form of transdermal creams and gels. Some of their notable products include:

• AndroForte® - A testosterone cream for men with hypogonadism.
• AndroFeme® - A testosterone cream for women with low testosterone levels.
• ProFeme® - A progesterone cream used in the management of menopause symptoms.

Research and Development

The company invests significantly in research and development to improve the efficacy and safety of its hormone replacement therapies. Lawley Pharmaceuticals collaborates with various research institutions and medical professionals to conduct clinical trials and studies.

Regulatory Approvals

Lawley Pharmaceuticals' products are approved by regulatory authorities in several countries, including the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States. The company adheres to stringent quality control measures to ensure the safety and efficacy of its products.

Corporate Social Responsibility

Lawley Pharmaceuticals is committed to corporate social responsibility (CSR) and engages in various initiatives to support community health and well-being. The company also focuses on sustainable practices in its manufacturing processes to minimize environmental impact.

See Also

• Hormone replacement therapy
• Testosterone
• Menopause
• Hypogonadism
• Therapeutic Goods Administration
• Food and Drug Administration